YIYasushi Iimura

Yasushi Iimura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yasushi Iimura has a total of 189 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mesial temporal involvement in epidermoid tumor–related temporal lobe epilepsy revealed by stereoelectroencephalography: illustrative case

    by Yasushi Iimura, Osamu Akiyama, Kazuki Nomura, Hiroharu Suzuki, Takumi Mitsuhashi, Tetsuya Ueda, Kazuki Nishioka, Hiroyuki Onuki, Hidenori Sugano, Akihide Kondo

    BACKGROUND: Intracranial epidermoid tumors are rare benign lesions that are typically nonepileptogenic; however, temporal lobe involvement may result in drug-resistant epilepsy. The relationship between the lesion and the epileptogenic network remains poorly understood, particularly due to limited electrophysiological evaluation of mesial temporal structures. OBSERVATIONS: A 52-year-old left-handed woman with drug-resistant temporal lobe epilepsy associated with an epidermoid tumor underwent staged surgical management. Initial resection of the posterior fossa component achieved histopathological diagnosis and brainstem decompression. Subsequent stereoelectroencephalography (SEEG) demonstrated seizure onset involving the hippocampal head and body and the mesial posterior temporal region. Functional mapping revealed language involvement in the posterior temporal cortex. Based on these findings, an anterior temporal lobectomy with partial hippocampal resection was performed to preserve cognitive function. Postoperatively, no new neurological deficits were observed and the patient achieved International League Against Epilepsy class III outcome, with seizures reduced to auras and a single focal impaired consciousness seizure. LESSONS: Epileptogenic networks in epidermoid tumor–related temporal lobe epilepsy may extend beyond the lesion to involve mesial temporal structures. This case highlights hippocampal involvement and the value of a staged SEEG-guided approach for identifying deep epileptogenic regions and guiding tailored surgical strategies, particularly in dominant hemisphere cases. https://thejns.org/doi/10.3171/CASE26341

  • Open Access

    Low-dose initiation and slow titration of fenfluramine in Lennox–Gastaut syndrome: a retention-oriented real-world study

    by Hiroharu Suzuki, Takumi Mitsuhashi, Tetsuya Ueda, Kazuki Nishioka, Kazuki Nomura, Hiroyuki Onuki, Hidenori Sugano, Yasushi Iimura, Akihide Kondo

    ObjectiveFenfluramine (FFA) is effective for Lennox–Gastaut syndrome (LGS); however, practical strategies for introducing FFA while maintaining treatment tolerability and long-term retention remain unclear. We conducted a single-center real-world study using a low-dose initiation and slow titration protocol.MethodsThis retrospective study included consecutive patients with LGS treated with FFA at a tertiary epilepsy center following its approval in Japan. FFA was initiated at 0.05 mg/kg/day in all patients and titrated at intervals of 30–60 days. Treatment retention, adverse events (AEs), tonic seizure frequency, and patient-centered functional changes were assessed.ResultsThirteen patients were included. Treatment was continued in 12 of 13 patients (92%). AEs occurred in 7 of 13 patients (54%), including appetite loss or weight reduction (6 patients) and somnolence or decreased activity (4 patients); these events were manageable with dose adjustment. Tonic seizures decreased in 12 of 13 patients, and ≥50% reduction was achieved in 8 of 13 patients based on seizure days per month. Seizure reduction prior to reaching 0.2 mg/kg/day was observed in 7 of 13 patients. Functional improvement, including enhanced alertness, activity, or social interaction, was documented in 5 of 13 patients (38%).ConclusionLow-dose initiation (0.05 mg/kg/day) with slow titration of FFA was associated with high treatment retention, clinically meaningful tonic seizure reduction, and observable functional improvements in patients with highly refractory LGS. These findings support the feasibility of a retention-oriented dosing strategy when introducing FFA in routine clinical practice.

  • Open Access

    First-year Experience with Brivaracetam in Japan: Real-world Data from Juntendo Epilepsy Center

    by Yasushi Iimura, Kazuki Nomura, Takumi Mitsuhashi, Hiroharu Suzuki, Tetsuya Ueda, Kazuki Nishioka, Taiji Tsunemi, Shinichi Ueno, Hidenori Sugano, Akihide Kondo

    Approximately 30% of patients still develop drug-resistant epilepsy despite the introduction of newer antiseizure medications. Brivaracetam, a high-affinity synaptic vesicle protein 2A ligand with a mechanism of action similar to that of levetiracetam, was only recently approved in Japan in June 2024 and became available at our institution in September 2024. Clinical data in real-world settings remain limited. To date, no real-world clinical data have been systematically reported in patients in Japan, and the present study aimed to characterize the initial real-world experience with Brivaracetam use shortly after its approval. We retrospectively analyzed 73 patients with focal epilepsy who initiated Brivaracetam at our center between September 2024 and August 2025, evaluating patient characteristics, seizure outcomes, treatment retention, and adverse events. Among 41 patients with at least 3 months of follow-up, seizure freedom was achieved in 5%, whereas 44% of patients were responders with ≥50% seizure reduction. Overall, 59 patients continued Brivaracetam, with a treatment retention rate of 76.5% and a mean treatment duration of 7.4 months. Adverse events were observed in 18 patients (24%), most frequently somnolence, followed by dizziness and irritability. Brivaracetam discontinuation occurred in 14 patients (19%), with psychiatric symptoms leading to discontinuation in only 3 patients (4%), a lower rate compared with prior reports of levetiracetam. These findings suggest that Brivaracetam is effective and generally well tolerated in patients in Japan with focal epilepsy. Future multicenter prospective studies with longer follow-up are warranted to further evaluate the role of Brivaracetam, including as monotherapy and in patients with multilobar epilepsy.

  • Open Access

    Longitudinal changes in developmental trajectory following early hemispherotomy in early infantile developmental and epileptic encephalopathy

    by Tetsuya Ueda, Hiroharu Suzuki, Takumi Mitsuhashi, Kazuki Nishioka, Kazuki Nomura, Takato Akiba, Shimpei Matsuda, Ayuko Igarashi, Hidenori Sugano, Yuri Urabe, et al.

  • Propagation concordance index reflects spatial proximity to the spike generator by linking interictal spikes with stimulation-induced neural propagation

    by Takumi Mitsuhashi, Hiroharu Suzuki, Kazuki Nishioka, Kazuki Nomura, Tetsuya Ueda, Yuki Takaki, Madoka Nakajima, Hidenori Sugano, Yasushi Iimura, Akihide Kondo

  • Open Access

    Ictal phase-amplitude coupling as a biomarker for seizure onset zone in neocortical epilepsy

    by Kazuki Nishioka, Yasushi Iimura, Takumi Mitsuhashi, Hiroharu Suzuki, Tetsuya Ueda, Kazuki Nomura, Yao Miao, Toshihisa Tanaka, Hiroshi Otsubo, Hidenori Sugano, et al.

    Objective: To assess ictal phase–amplitude coupling (PAC) dynamics during seizure generation and explore whether ictal PAC analysis can help identify the seizure onset zone (SOZ) in neocortical epilepsy.Methods: We analyzed ictal intracranial electroencephalography recordings from 22 seizures in six patients with drug-resistant neocortical epilepsy who achieved International League Against Epilepsy Class I outcomes following resection surgery. PAC strength was quantified using the modulation index (MI), computed by coupling the amplitude of high-frequency bands (ripples: 80–200 Hz; fast ripples: 200–300 Hz) with the phase of slow-wave bands (1–2 Hz, 2–3 Hz, 3–4 Hz and 4–8 Hz). MI values were compared across SOZ, peri-SOZ (adjacent electrodes), and non-SOZ regions. Localization accuracy was evaluated using the area under the curve (AUC) from receiver operating characteristic curve analysis.Results: Across all PAC between ripples and slow wave bands, MI values were significantly higher in the SOZ compared to the peri-SOZ and non-SOZ regions (p < 0.001). During the late phase of seizure onset, MIRipples/4–8 Hz was also significantly higher in the peri-SOZ region than in the non-SOZ region (p < 0.001). MIRipples/4–8 Hz (AUC: 0.853) and MIRipples/3–4 Hz (AUC: 0.846) demonstrated strong SOZ localization performance. MIRipples/3–4 Hz distinguished SOZ from peri-SOZ (AUC: 0.800).Conclusion: Elevated MI during seizure onset accurately localized the SOZ in neocortical epilepsy. Ictal PAC may be a useful biomarker for identifying SOZ in neocortical epilepsy.


  • Open Access

    Upward eye deviation as a precursor to epileptic spasms: A case successfully treated with early corpus callosotomy without adrenocorticotropic hormone therapy

    by Yasushi Iimura, Hiroharu Suzuki, Takumi Mitsuhashi, Tetsuya Ueda, Kazuki Nishioka, Kazuki Nomura, Shimpei Abe, Takato Akiba, Shimpei Matsuda, Hidenori Sugano, et al.


  • Neurodevelopmental milestone acquisition following early hemispherotomy in Sturge-Weber syndrome

    by Yasushi Iimura, Hiroharu Suzuki, Takumi Mitsuhashi, Tetsuya Ueda, Kazuki Nishioka, Kazuki Nomura, Shimpei Abe, Mitsuru Ikeno, Ayuko Igarashi, Mika Nakazawa, et al.


  • Open Access

    Spontaneous regression of epileptogenic pilocytic astrocytoma with FGFR1-TACC1 fusion

    by Ko Horikoshi, Yasushi Iimura, Hiroharu Suzuki, Mario Suzuki, Hidenori Sugano, Akihide Kondo

    Introduction Pilocytic astrocytoma (PA) is the most common pediatric tumor, typically located in the cerebellum, with spontaneous regression observed mainly in patients with neurofibromatosis type 1 (NF1). However, spontaneous regression of PA without NF1 is rarely reported. Case Presentation Here, we describe a case of spontaneous regression of PA without NF1, located in the left frontal lobe with FGFR1-TACC1 fusion, in a 14-year-old boy who presented with epilepsy. Initial MRI revealed a lesion in the left middle frontal gyrus, and subsequent follow-up MRI demonstrated spontaneous regression. Despite this regression, the patient’s seizures persisted, leading to epileptic focus resection. Pathological examination confirmed PA with characteristic histological findings and FGFR1-TACC1 fusion. Conclusion This case suggests that FGFR1-TACC1 fusion may be linked to spontaneous regression of PA, even in the absence of NF1. Surgical intervention may remain necessary in cases of epilepsy associated with PA, regardless of tumor regression.

  • Open Access

    Effect of vagus nerve stimulation against generalized seizure and status epilepticus recurrence

    by Yasushi Iimura, Hiroharu Suzuki, Takumi Mitsuhashi, Tetsuya Ueda, Kazuki Nishioka, Kou Horikoshi, Kazuki Nomura, Hidenori Sugano, Akihide Kondo

    Objective: Vagus nerve stimulation (VNS) is a palliative surgery for drug-resistant epilepsy. The two objectives of this study were to (1) determine the seizure type most responsive to VNS and (2) investigate the preventive effect on status epilepticus (SE) recurrence.Methods: We retrospectively reviewed 136 patients with drug-resistant epilepsy who underwent VNS implantation. We examined seizure outcomes at 6, 12, and 24 months following implantation of VNS as well as at the last visit to the Juntendo Epilepsy Center. Univariate analysis and multivariate logistic regression models were used to estimate the prognostic factors.Results: 125 patients were followed up for at least 1 year after VNS implantation. The percentage of patients with at least a 50% reduction in seizure frequency compared with prior to VNS implantation increased over time at 6, 12, and 24 months after VNS implantation: 28, 41, and 52%, respectively. Regarding overall seizure outcomes, 70 (56%) patients responded to VNS. Of the 40 patients with a history of SE prior to VNS implantation, 27 (67%) showed no recurrence of SE. The duration of epilepsy, history of SE prior to VNS implantation and seizure type were correlated with seizure outcomes after VNS implantation in univariate analysis (p = 0.05, p < 0.01, and p = 0.03, respectively). In multivariate logistic regression analysis, generalized seizure was associated with VNS response [odds ratio (OR): 4.18, 95% CI: 1.13–15.5, p = 0.03]. A history of SE prior to VNS implantation was associated with VNS non-responders [(OR): 0.221, 95% CI: 0.097–0.503, p < 0.01]. The duration of epilepsy, focal to bilateral tonic–clonic seizure and epileptic spasms were not significantly associated with VNS responders (p = 0.07, p = 0.71, and p = 0.11, respectively).Conclusion: Following 125 patients with drug-resistant epilepsy for an average of 69 months, 56% showed at least 50% reduction in seizure frequency after VNS implantation. This study suggests that generalized seizure is the most responsive to VNS, and that VNS may reduce the risk of recurrence of SE. VNS was shown to be effective against generalized seizure and also may potentially influence the risk of further events of SE, two marker of disease treatment that can lead to improved quality of life.